Antibody–drug conjugates (ADCs) are novel drugs that exploit the specificity of a
monoclonal antibody (mAb) to reach target antigens expressed on cancer cells for the …

Antibody-drug conjugates (ADCs) have emerged as a revolutionary therapeutic class,
combining the precise targeting ability of monoclonal antibodies with the potent cytotoxic …

Simple Summary Monoclonal antibodies (mAbs) have the ability to specifically target tumor-
cell antigens. This unique property has led to their use in the delivery of radioisotopes to …

89Zr is an emerging radionuclide that plays an essential role in immuno-positron emission
tomography (PET) imaging. The long half-life of 89Zr (t1/2= 3.3 days) is favorable for …

Radiolabeled peptides are a relatively new, very specific radiotracer group, which is still
expanding. This group is very diverse in terms of peptide size. It contains very small …

The identification of molecular drivers of disease and the compelling rise of biotherapeutics
have impacted clinical care but have also come with challenges. Such therapeutics include …

Radiolabelling small molecules with beta-emitters has been intensively explored in the last
decades and novel concepts for the introduction of radionuclides continue to be reported …

Effective treatments for de novo and treatment-emergent small-cell/neuroendocrine (t-
SCNC) prostate cancer represent an unmet need for this disease. Using metastatic biopsies …

Diagnostic molecular images, obtained by positron emission tomography (PET), have
successfully functioned as sensitive tools for detecting and monitoring the treatment of …

The combination of targeting ligands and fluorescent dyes is a powerful strategy to observe
cell types and tissues of interest. Conjugates of peptides, proteins, and, in particular …